secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0000950170-23-008457
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC Pharma reports Q4 2022 cash of $228.2M; Pfizer invests $25M; Phase 1b data expected H2 2023
--------------------------------------------------------------------------------

- Cash and investments $228.2M at Dec 31, 2022; runway into first half of 2025.
- Pfizer purchased 5.4M shares at $4.65/share for $25M equity investment; collaboration on ORIC-533 + elranatamab combo.
- R&D expenses $16.3M in Q4 2022 vs $16.7M in Q4 2021; full-year R&D $61.7M vs $56.9M.
- Initial Phase 1b data for ORIC-533, ORIC-114, and ORIC-944 expected in second half of 2023.
- Selected a PLK4 inhibitor development candidate; Jeff Settleman (Pfizer) joined Scientific Advisory Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000095017023008457/0000950170-23-008457-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000095017023008457/oric-20230316.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-008457

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer